XNAS
COSM
Market cap31mUSD
Oct 08, Last price
0.31USD
1D
-2.03%
1Q
7.41%
Jan 2017
-98.47%
IPO
-87.42%
Name
Cosmos Health Inc
Chart & performance
P/E
—
P/S
0.48
EPS
—
Div yield, %
—
Shrs. gr., 5y
124.40%
Rev. gr., 5y
3.33%
Revenues
65m
+19.93%
Net income
-19m
L+18.30%
CFO
-8m
L+9.47%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.
Key people
Dimitrios Goulielmos
Director · since 2016
John James Hoidas
Director · since 2016
Grigorios Siokas
Chairman of the Board, Chief Executive Officer, Chief Financial Officer · since 2016
Headquarters & legal address
5725 Bravo Ave
Reno, NV 89506
US
Reno, NV 89506
US
Previous name
PRIME ESTATES & DEVELOPMENTS, INC.
Previous name
COSMOS HOLDINGS INC.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||